A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia
What is the goal of the study?
This is a Phase 3 open-label, multicenter study to evaluate the safety and efficacy of BMN 111 in children with ACH who complete Study 111-301. Eligible subjects who have completed 1 year of BMN 111 or placebo treatment in Study 111-301 may be enrolled in the 111-302 extension study and will receive a daily dose of 15 ?g/kg BMN 111 by subcutaneous injection. To minimize bias, during dosing in 111-302 investigators and subjects will continue to be blinded to the subjects? treatment allocation in 111-301.
Who can participate in the study?
Please contact the study team listed below to learn more.